Edition:
United Kingdom

Camurus AB (CAMX.ST)

CAMX.ST on Stockholm Stock Exchange

129.50SEK
14 Dec 2017
Change (% chg)

-0.50kr (-0.38%)
Prev Close
130.00kr
Open
130.00kr
Day's High
130.25kr
Day's Low
128.00kr
Volume
30,321
Avg. Vol
28,955
52-wk High
145.75kr
52-wk Low
103.00kr

Summary

Name Age Since Current Position

Per Wallstrom

67 2015 Independent Chairman of the Board

Fredrik Tiberg

52 Chief Executive Officer, Director

Eva Pinotti-Lindqvist

52 2014 Chief Financial Officer

Torsten Malmstrom

47 2013 Vice President, Technical Operations

Rein Piir

59 2015 Vice President, Investor Relations

Markus Johnsson

43 2009 Vice President, Pharmaceutical and Analytical Development

Margareta Linden

61 2004 Vice President, Project Management and Planning

Agneta Svedberg

52 2015 Vice President, Clinical and Regulatory Development

Fredrik Joabsson

43 2011 Vice President, Business Development and Alliance Management

Richard Jameson

2016 Chief Commercial Officer

Martin Jonsson

55 2013 Director

Per-Anders Abrahamsson

66 2006 Independent Director

Marianne Dicander Alexandersson

58 2015 Independent Director

Svein Mathisen

59 2010 Independent Director

Kerstin Valinder Strinnholm

56 2015 Independent Director

Biographies

Name Description

Per Wallstrom

Mr. Per Olof Wallstrom has been Independent Chairman of the Board at Camurus AB since 2015. He has been Director of the Company since 2010. He is Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee of the Company. He holds Master of Science in Pharmacy from Uppsala University. He has been in senior management at Merck Sharpe & Dohme, AstraZeneca, Pharmacia and Bristol-Myers Squibb and has served as CEO of Q-Med, Melacure and Karo Bio AB. He is currently Chairman of the Board of MB Erikssons Bygg & Fastighet AB, Arosgruppen Fastigheter Fjardingen AB, Arosgruppen Holding AB, Neo Dynamics AB and Patients Pending Ltd, Board member of Hansa Medical AB and Arosia Communication AB as well as Deputy Board member of Reabyran AB. He was previously Chairman of the Board of Aros Arkitekter AB and Chemilia AB as well as Board member of Mediplast AB and Aggal Invest AB.

Fredrik Tiberg

Mr. Fredrik Tiberg serves as Chief Executive Officer and Director at Camurus AB. He has been CEO of the Company since 2003. He holds Master of Science in Chemical Engineering from Lund Institute of Technology. He also holds Ph.D. in physical chemistry and associate professor of physical chemistry (surface chemistry) from Lund University. He has been Section Manager at the Institute for Surface Chemistry, adjunct professor of surface chemistry at Lund University, and visiting professor of physical and theoretical chemistry at the University of Oxford. He is currently Board member and CEO of Camurus Development AB and Bioimplant Scandinavia AB as well as Board member of Medicon Valley Alliance. He was previously CEO of Heptahelix AB.

Eva Pinotti-Lindqvist

Ms. Eva Pinotti-Lindqvist has been Chief Financial Officer at Camurus AB since 2014. She holds Bachelor of Science in Business Administration from Lund University. She has been CFO and Vice President Business Development for EQL Pharma AB, Market analyst for Nordic Drugs AB and financial consultant for Poolia AB, Controller of Svedala Svenska AB and Finance Manager for Poseidon Yacht Charter AB. She is Owner of JOCE Hast & Ho. She was previously Board member of EQL Pharma OY and Board member of EQL Pharma Int AB.

Torsten Malmstrom

Mr. Torsten Malmstrom has been Vice President, Technical Operations at Camurus AB since 2013. He holds Ph.D. in chemistry from Lund University. He has been Team Manager at Astra Zeneca. He was previously Director Pharmaceutical Development for Zealand Pharma and Director of Development for Polypeptide.

Rein Piir

Mr. Rein Piir has been Vice President, Investor Relations at Camurus AB since 2015. He holds M.Sc. in Business Administration from Uppsala University. He has many years of experience as advisor to listed companies, including as head of research at Carnegie Investment Bank AB and strategist at Alecta. He has 14 years as CFO/Head of Investor Relations at Medivir AB, and three years as an auditor at PricewaterhouseCoopers AB. He is Chairman of the Board and CEO for Piir & Partner AB, as well as Board member of Integrative Research Laboratories Sweden AB, Trygga Pengar i Mobilen Sverige AB and L. E. Svensson Snickeri AB. He was previously Board member of HW Svenskt Reklamscreen AB and Medivir Personal AB.

Markus Johnsson

Mr. Markus Johnsson has been Vice President, Pharmaceutical and Analytical Development at Camurus AB since 2009. He holds Ph.D. in physical chemistry and M.Sc. in chemistry from Uppsala University. He has been Postdoctoral researcher at the University of Groningen. Senior Scientist at Uppsala University, Senior Research Scientist and Manager for Parenteral Drug Delivery Systems at Camurus.

Margareta Linden

Ms. Margareta Linden has been Vice President, Project Management and Planning at Camurus AB since 2004. She holds Bachelor of Science in chemistry and biology and Ph.D. in Zoophysiology from Lund University. She has been Associate professor of experimental pulmonary medicine at Lund University. She has many years of experience from various positions within preclinical and clinical research and development in the pharmaceutical industry (Draco, AstraZeneca). She is Owner of BioLinden (sole trader).

Agneta Svedberg

Ms. Agneta Svedberg has been Vice President, Clinical and Regulatory Development at Camurus AB since 2015. She holds Master of Science in Radiophysics and Executive MBA, Executive Foundation Lund (EFL), B.Sc. in Medicine, all from Lund University. She has over 20 years of experience in drug development, including two years as COO for Zealand Pharma A/S, two years as CEO of Cantargia AB and Senior Vice President, Clinical Development at Genmab A/S for ten years. She was previously COO for Zealand Pharma A/S, CEO for Cantargia AB.

Fredrik Joabsson

Mr. Fredrik Joabsson has been Vice President, Business Development and Alliance Management at Camurus AB since 2011. He holds Doctorate in Philosophy in physical chemistry and M.Sc. in chemistry from Lund University. He has 14 years of experience in drug discovery through various positions in research and development and business development at Camurus.

Richard Jameson

Mr. Richard Jameson has been appointed Chief Commercial Officer at Camurus AB effective as of during 2016. Richard Jameson has broad experience from different commercial roles across a number of specialty pharmaceutical companies, including Schering Plough, Ferring and Indivior, where for the last three years he has been serving as Area Director EMEA. In this role he was responsible for the leadership of a commercial organization across Europe, the Middle-East and Africa, focusing on the opioid dependence therapeutic area.

Martin Jonsson

Mr. Martin Jonsson has been Director of Camurus AB since 2013. He is Chairman of the Audit Committee and Member of the Remuneration Committee and Nomination Committee of the Company. He holds Master of Science in Business Administration from Lund University. He has over 25 years of combined experience in corporate governance and working in senior positions in various industries such as medical devices, biotechnology and industrial kitchens. He is Board member of Camurus Development AB, Bioimplant Scandinavia AB, Aimpoint AB and Granuldisk AB. Board member and CEO of Sandberg Development AB, Deputy for Ogardsros AB, Lesurak AB and ANORK AB, and External signatory for Aimpoint Sweden AB. He was previously Deputy for Bioimplant Scandinavia AB. External signatory for Bioimplant Scandinavia AB, Camurus AB, Camurus Development AB, Granuldisk AB, Aimpoint AB and Sandberg Development AB.

Per-Anders Abrahamsson

Mr. Per-Anders Abrahamsson has been Independent Director at Camurus AB since 2006. He holds Doctor of Medicine from Lund University, Ph.D., associate professor and professor of urology. He has been Physician at Skane University Hospital and former Secretary General of the European Association of Urology (EAU). He is currently Board member of Medisport AB and GOAR Holding A/S as well as Executive Medical Director of Ferring Pharmaceutical.

Marianne Dicander Alexandersson

Ms. Marianne Dicander Alexandersson has been Independent Director at Camurus AB since 2015. She holds Master of Science in Chemical Engineering from Chalmers University of Technology. She has many years of experience in the life science industry and from board work, including as CEO of Kronans Droghandel, Global Health Partner and the Sixth AP Fund, deputy CEO of Apoteket AB and positions in quality and market development at Pharmacia, Imperial Chemical Industries and Volvo. She also serves at Enzymatica AB (publ), Recipharm AB (publ) and West Atlantic, Chairman of the Board and CEO of MDA Management AB, member of the council at Skandia, Chairman of Sahlgrenska Science Park and member of the Advisory Council of the Dental and Pharmaceutical Benefits Agency. She was previously Chairman of the Board for Global Health Partner Swe AB, Board member in Apoteksakademin i Sverige AB, Bariatric and Diabetes Center Ajman AB, Castellum AB, Chalmers Tekniska Hogskola AB, Easy Lighting Scandinavia AB, Ideella foreningen Svenskt Naringsliv med firma Svenskt Naringsliv, Molnlycke AB, Molnlycke Holding AB and MHC Sweden AB. She was CEO of Global Health Partner AB, external CEO of GHP Specialty Care AB (publ), external CEO of the Sixth AP Fund and external deputy CEO of Apoteket AB (publ).

Svein Mathisen

Mr. Svein Mathisen has been Director at Camurus AB since 2010. He is Member of the Audit Committee and the Remuneration Committee. He holds Master of Science in engineering physics from the Norwegian University of Science and Technology. He has more than 25 years of experience in various senior positions in the Norsk Hydro Group and as CEO of BioInvent International AB. He is Chairman of the Boards of iCell Science AB and Gabather AB, Board member of Athera Biotechnologies AB, Genagon Technologies AB and Arild Capital AB. He was previously Board member and CEO of BioInvent International AB, Chairman of the Board of Biotec Pharmacon ASA and Board member of the industry organization Sweden Bio.

Kerstin Valinder Strinnholm

Ms. Kerstin Valinder Strinnholm has been Independent Director at Camurus AB since 2015. She holds a degree from the School of Journalism at the University of Gothenburg and has many years of experience in sales, marketing and business development from senior positions at Astra/AstraZeneca and Nycomed/Takeda. She is Board member of Corline Biomedical AB, KVS Invest AB and Cavastor AB. She was previously EVP Business Development for the Nycomed Group.